Results 161 to 170 of about 2,974 (211)
Some of the next articles are maybe not open access.
Dalbavancin or Oritavancin for Skin Infections
New England Journal of Medicine, 2014To the Editor: Boucher et al. (June 5 issue)1 report the results of DISCOVER 1 and DISCOVER 2, and in the same issue Corey et al.2 report the results of SOLO I. These randomized trials investigated the efficacy of oritavancin and dalbavancin in acute bacterial skin and skin-structure infections.
Helen W, Boucher +2 more
exaly +7 more sources
Oritavancin: A Novel Lipoglycopeptide
The Consultant Pharmacist, 2016To review the pharmacology, pharmacokinetics, drug interactions, microbiologic profile, dosage and administration, safety, clinical efficacy, and potential place in therapy for the new lipoglycopetide, oritavancin.MEDLINE and PubMed searches of available literature in English were conducted for oritavancin.
Jacob, Mattox +2 more
openaire +2 more sources
Oritavancin – an investigational glycopeptide antibiotic
Expert Opinion on Investigational Drugs, 2006Antibiotics save countless lives each year; however, increasing rates of drug-resistant bacteria have limited antibiotic selection. Currently, there are few available options for treating resistant Gram-positive organisms. Oritavancin, a novel glycopeptide antibiotic with bactericidal activity, has been developed and recently completed the first round ...
Ward, Kristina E. +2 more
openaire +3 more sources
Oritavancin: An investigational lipoglycopeptide antibiotic
American Journal of Health-System Pharmacy, 2013The pharmacology, unique pharmacokinetic-pharmacodynamic profile, and potential future role of oritavancin in combating multidrug-resistant infections are reviewed, with an emphasis on efficacy data from Phase II and III clinical trials.Oritavancin has been shown to have potent in vitro activity against vancomycin-resistant enterococci (VRE) and ...
Karaoui, Lamis R. +2 more
openaire +3 more sources
Oritavancin: First Global Approval
Drugs, 2014Oritavancin (Orbactiv(®)) is a lipoglycopeptide antibacterial drug with activity against Gram-positive bacteria developed by The Medicines Company as a single-dose treatment for acute bacterial skin and skin structure infections (ABSSSI). The drug received its first global approval for this indication in the US in August 2014, and is under regulatory ...
openaire +2 more sources
Oritavancin: A Long-Acting Antibacterial Lipoglycopeptide
Future Microbiology, 2016Oritavancin is a new lipoglycopeptide antibacterial agent with an exceptionally long terminal half-life and a rapid bactericidal effect. Multiple mechanisms of action lead to a broad activity against Gram-positive bacteria, such as staphylococci, streptococci and enterococci, including methicillin-resistant Staphylococcus aureus. Its long terminal half-
Achim J, Kaasch, Harald, Seifert
openaire +2 more sources
Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab
Journal of the American Pharmacists Association, 2014Antibacterial agents Skin and skin structure infections are most often caused by Grampositive bacteria such as streptococci and staphylococci. The number of these infections that are caused by methicillin-resistant Staphylococcus aureus (MRSA) has rapidly increased in recent years in both the community and hospital settings.
Daniel A, Hussar, Angelique, Nguyen
openaire +2 more sources
Oritavancin for skin infections
Drugs of Today, 2008Oritavancin (LY-333328) is a semisynthetic lipoglycopeptide for the treatment of serious infections with Gram-positive pathogens, especially methicillin-resistant Staphylococcus aureus and complicated skin and soft tissue infections. A New Drug Application for oritavancin administered intravenously once daily for 3 to 7 days for complicated skin and ...
openaire +2 more sources
Electrocardiographic Effects of a Supratherapeutic Dose of Oritavancin
Clinical Pharmacology in Drug Development, 2016AbstractThe purpose of this study was to measure oritavancin's electrocardiographic effects at a supratherapeutic dose of 1600 mg given intravenously (IV) over 3 hours. A cohort of 150 healthy volunteers were randomized to receive placebo, oritavancin, or oral moxifloxacin 400 mg in a parallel designed thorough QT study. A supratherapeutic mean maximum
Jay W, Mason +4 more
openaire +2 more sources